These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 18303004)

  • 1. Detecting trends in noisy data series: application to biomarker series.
    Bellera CA; Hanley JA; Joseph L; Albertsen PC
    Am J Epidemiol; 2008 May; 167(9):1130-9. PubMed ID: 18303004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A statistical evaluation of rules for biochemical failure after radiotherapy in men treated for prostate cancer.
    Bellera CA; Hanley JA; Joseph L; Albertsen PC
    Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1357-63. PubMed ID: 19395198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hierarchical changepoint models for biochemical markers illustrated by tracking postradiotherapy prostate-specific antigen series in men with prostate cancer.
    Bellera CA; Hanley JA; Joseph L; Albertsen PC
    Ann Epidemiol; 2008 Apr; 18(4):270-82. PubMed ID: 18374279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicting time to prostate cancer recurrence based on joint models for non-linear longitudinal biomarkers and event time outcomes.
    Pauler DK; Finkelstein DM
    Stat Med; 2002 Dec; 21(24):3897-911. PubMed ID: 12483774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bayesian adjustment for covariate measurement errors: a flexible parametric approach.
    Hossain S; Gustafson P
    Stat Med; 2009 May; 28(11):1580-600. PubMed ID: 19226564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correction of prostate-specific antigen velocity for variation may improve prediction of cancer following prostate repeat biopsy.
    Kumar A; Godoy G; Taneja SS
    Can J Urol; 2009 Jun; 16(3):4655-9. PubMed ID: 19497172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Re: Correction of prostate-specific antigen velocity for variation may improve prediction of cancer following prostate repeat biopsy.
    Singh A
    Can J Urol; 2009 Jun; 16(3):4659. PubMed ID: 19497173
    [No Abstract]   [Full Text] [Related]  

  • 8. The clinical significance in healthy men of the association between obesity related plasma hemodilution and tumor marker concentration.
    Chang IH; Ahn SH; Han JH; Kim TH; Kim YS; Myung SC
    J Urol; 2009 Feb; 181(2):567-72; discussion 572-3. PubMed ID: 19084848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A simple and general change-point identifier.
    Riffenburgh RH; Cummins KM
    Stat Med; 2006 Mar; 25(6):1067-77. PubMed ID: 16345027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prostate specific antigen: utilization modalities and interpretation].
    Hannoun-Levi JM; Ginot A; Thariat J
    Cancer Radiother; 2008 Dec; 12(8):848-55. PubMed ID: 18539498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repeating an abnormal prostate-specific antigen (PSA) level: how relevant is a decrease in PSA?
    Connolly D; Black A; Murray LJ; Nambirajan T; Keane PF; Gavin A
    Prostate Cancer Prostatic Dis; 2009; 12(1):47-51. PubMed ID: 18762815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes following active surveillance of men with localized prostate cancer diagnosed in the prostate specific antigen era.
    Ercole B; Marietti SR; Fine J; Albertsen PC
    J Urol; 2008 Oct; 180(4):1336-9; discussion 1340-1. PubMed ID: 18707696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using spectral moments of spiral networks based on PSA/mass spectra outcomes to derive quantitative proteome-disease relationships (QPDRs) and predicting prostate cancer.
    Ferino G; González-Díaz H; Delogu G; Podda G; Uriarte E
    Biochem Biophys Res Commun; 2008 Jul; 372(2):320-5. PubMed ID: 18503754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bayesian hierarchical modeling of drug stability data.
    Chen J; Zhong J; Nie L
    Stat Med; 2008 Jun; 27(13):2361-80. PubMed ID: 18338325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of obesity on the diagnosis of prostate cancer using a modern extended biopsy scheme.
    Pruthi RS; Swords K; Schultz H; Carson CC; Wallen EM
    J Urol; 2009 Feb; 181(2):574-7; discussion 578. PubMed ID: 19084847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Bayesian hierarchical model for the estimation of two incomplete surveillance data sets.
    Buenconsejo J; Fish D; Childs JE; Holford TR
    Stat Med; 2008 Jul; 27(17):3269-85. PubMed ID: 18314934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of prostate-specific antigen in prostate cancer.
    Liang SL
    MLO Med Lab Obs; 2008 Oct; 40(10):54, 56-7. PubMed ID: 18988558
    [No Abstract]   [Full Text] [Related]  

  • 18. Total prostate specific antigen stability confirmed after long-term storage of serum at -80C.
    Reed AB; Ankerst DP; Leach RJ; Vipraio G; Thompson IM; Parekh DJ
    J Urol; 2008 Aug; 180(2):534-7; discussion 537-8. PubMed ID: 18550121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [PSA based screening for prostatic cancer].
    Johansen TE
    Tidsskr Nor Laegeforen; 2008 Nov; 128(22):2612-4. PubMed ID: 19023357
    [No Abstract]   [Full Text] [Related]  

  • 20. Enhancement of sensitivity and specificity by surface modification of carbon nanotubes in diagnosis of prostate cancer based on carbon nanotube field effect transistors.
    Kim JP; Lee BY; Lee J; Hong S; Sim SJ
    Biosens Bioelectron; 2009 Jul; 24(11):3372-8. PubMed ID: 19481922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.